{
    "nctId": "NCT00595296",
    "briefTitle": "GeneSearch\u2122 Breast Lymph Node (BLN) Assay Post Approval Study",
    "officialTitle": "GeneSearch\u2122 Breast Lymph Node (BLN) Assay Post Approval Study",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 461,
    "primaryOutcomeMeasure": "To estimate the positive predictive concordance (PPC) between the GeneSearch\u2122 BLN Assay and histology as routinely practiced.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre-operatively established diagnosis of invasive carcinoma of the breast\n* Scheduled for axillary sentinel lymph node dissection as per standard of care at the clinical site for newly diagnosed breast cancer patients\n* Patients for whom the GeneSearch\u2122 BLN Assay will be used intra-operatively to make a decision for an axillary lymph node dissection\n* 18 years of age or older\n* Female or male\n* Willing and able to give informed consent to participate in the study\n\nExclusion Criteria:\n\n* Previous diagnosis of lymphoma\n* Subjects participating in other research studies that would interfere with their full participation in this study\n* Patients and/or conditions with 'interfering substances' as listed in the IFU.\n* Patients who have had any pre-operative treatment for breast cancer including neoadjuvant and/or hormonal intervention such as aromatase inhibitors or tamoxifen",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}